An overview of emerging immunotargets of genitourinary tumors

Rodolfo Montironi, Matteo Santoni, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Marina Scarpelli

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Emerging immunotherapies targeting immune checkpoints and tumor associated antigens are leading to important clinical advances and providing a new weapon in patients with prostate (PCa) and bladder cancer (BC) and, in particular, with renal cell carcinoma (RCC). The possibility to integrate these agents in the current therapeutic scenario or genitourinary tumors, both in sequential or combined approaches, relies on a more profound comprehension of the protumorigenic activity of the immune system and of the mechanisms of cancer-related immunosuppression. In this regards, neutrophils, T and B lymphocytes and tumor-associated macrophages (TAMs) are implicated in the pathogenesis, progression and development of drug resistance in genitourinary tumors. This review is an overview on the recent insights concerning the role of immune cells in this context.

Original languageEnglish (US)
Pages (from-to)750-756
Number of pages7
JournalCurrent Drug Targets
Issue number7
StatePublished - Jun 1 2016


  • Genitourinary tumors
  • Immunotherapy
  • Lymphocytes
  • Macrophages
  • Neutrophils

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'An overview of emerging immunotargets of genitourinary tumors'. Together they form a unique fingerprint.

Cite this